Short Interest in Spectral Diagnostics Inc. (OTCMKTS:EDTXF) Drops By 41.5%

Spectral Diagnostics Inc. (OTCMKTS:EDTXF) was the target of a significant decline in short interest in August. As of August 31st, there was short interest totaling 13,085 shares, a decline of 41.5% from the August 15th total of 22,385 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 18,209 shares, the days-to-cover ratio is presently 0.7 days.

Spectral Diagnostics Price Performance

Shares of OTCMKTS:EDTXF opened at $0.92 on Thursday. Spectral Diagnostics has a 1 year low of $0.81 and a 1 year high of $1.15. The firm has a market capitalization of $268.95 million, a price-to-earnings ratio of -9.15 and a beta of 0.16. The business’s 50 day moving average price is $0.97 and its 200-day moving average price is $0.98.

Spectral Diagnostics Company Profile

Spectral Diagnostics, now known as Spectral Medical Inc, is a Canadian medical-device and biotechnology company focused on products for the diagnosis and treatment of sepsis and septic shock. The company’s work centers on identifying endotoxemia, a condition in which bacterial endotoxins enter the bloodstream and can contribute to severe systemic inflammation.

Spectral’s primary diagnostic product is the Endotoxin Activity Assay (EAA), a blood test designed to measure a patient’s endotoxin activity and help identify individuals who may be at increased risk of developing severe sepsis.